Back to search results
NCT07638748

Feasibility, Usability, and Acceptability of Virtual Reality-Based Cognitive and Physical Rehabilitation in Individuals With Mild Cognitive Impairment

Not Yet Recruiting
NAAges 55–90InterventionalDevice feasibility
The University of Texas Health Science Center, Houston
~10 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:VR sessions

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility as assessed by the recruitment rate
Measured over from baseline to end of intervention (6 weeks)
+8 more outcomes measured

Conditions

Mild Cognitive Impairment
Subjective Cognitive Decline (SCD)

Explore related trials

Mild cognitive disorderSubjective Cognitive Decline

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Seema Aggarwal, PhD, APRN, AGNP-C · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center, Houston

Who to contact

Seema S Aggarwal, PhD, APRN, AGNP-C
[email protected]
(713) 500-9946
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Clinical diagnosis of MCI (MoCA 18-26) or self-reported subjective cognitive decline (SCD)
Capacity to provide informed consent
Able to provide own transportation to sessions
Speaks and understands English
Ambulatory

Exclusion

Uncontrolled seizures or epilepsy
Severe psychiatric illness or active suicidality
Inability to follow instructions or tolerate VR (severe motion sickness)
Cognitive impairment as a result of a known cause (e.g., dementia, stroke, Traumatic Brain Injury (TBI), medications, etc.)
Any condition that the research team determines would interfere with safe participation

What this trial measures

  • Feasibility as assessed by the recruitment ratefrom baseline to end of intervention (6 weeks)
  • Feasibility as assessed by the retention ratefrom baseline to end of intervention (6 weeks)
  • Feasibility as assessed by the session completion ratefrom baseline to end of intervention (6 weeks)
  • Usability as assessed by the System Usability Scale (SUS)Post-intervention only (Final visit at 6 weeks)

    The System Usability Scale (SUS) is a validated 10-item questionnaire used to assess participants' perceived usability of the intervention. each rated on a 5-point Likert scale from 1 = Strongly Disagree, 2 = Disagree 3 = Neutral ,4 = Agree, 5 = Strongly Agree. Scores range from 0 to 100, with higher scores indicating greater usability.

  • Acceptability / Presence as assessed by the Presence Questionnaire (PQ)Post-intervention only (Final visit at 6 weeks)

    This is a 29 item questionnaire, each is scored on a seven-point Likert-type scale with a score range form 29-203. Higher scores indicate a greater sense of presence or immersion in the virtual environment.

  • Tolerability / Side Effects as assessed by the Simulator Sickness Questionnaire (SSQ)Before + immediately After each VR session

    This is a 16 item questionnaire and each is scored form 0(none) to 3(severe). Scores are combined using weighted subscales to generate a total score, with higher scores indicating greater simulator sickness

  • Adherence / Engagement as assessed by the session attendance as entered in VR system logsPost-intervention only (Final visit at 6 weeks)
  • Adherence / Engagement as assessed by the time from start to end of VR session as entered in VR system logsPost-intervention only (Final visit at 6 weeks)
  • Adherence / Engagement as assessed by the number of repetitions of the activity as indicated by device metricsPost-intervention only (Final visit at 6 weeks)